Cargando…

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia

Detalles Bibliográficos
Autores principales:	Aomar-Millán, Ismael F., Salvatierra, Juan, Raya Álvarez, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546534/ https://www.ncbi.nlm.nih.gov/pubmed/36247068 http://dx.doi.org/10.1016/j.medcle.2022.04.017

Ejemplares similares

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Efecto del tocilizumab frente a cuidado estándar en pacientes adultos hospitalizados con neumonía por COVID-19 moderada-grave
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab: comentario
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2023)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Cardona-Pascual, Ignacio, et al.
Publicado: (2022)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Cardona-Pascual, Ignacio, et al.
Publicado: (2022)

Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
por: Mandal, M., et al.
Publicado: (2022)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
por: Salvatierra, Juan, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment
por: Yurttutan, Sadık, et al.
Publicado: (2021)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients
por: Piconi, Stefania, et al.
Publicado: (2023)

Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Liu, Bin, et al.
Publicado: (2020)

Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia
por: Gokhale, Yojana, et al.
Publicado: (2020)

Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial
por: Naik, Naveen B, et al.
Publicado: (2021)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy
por: van Duin, David, et al.
Publicado: (2011)

Could surgery be the gold standard in moderate and severe ischaemic colitis? Atypical case description and review of literature
por: Virdis, F., et al.
Publicado: (2014)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis
por: Luo, Lili, et al.
Publicado: (2022)

Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM
por: Klopfenstein, Timothée, et al.
Publicado: (2022)

Use of tocilizumab in multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2
por: Banday, Aaqib Zaffar, et al.
Publicado: (2021)

Severe Pneumonia and Human Bocavirus in Adult
por: Kupfer, Bernd, et al.
Publicado: (2006)

Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination
por: Chhabra, Saurabh, et al.
Publicado: (2022)

‘Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM’ – Author's reply
por: Broman, Niklas, et al.
Publicado: (2022)

Tocilizumab administration in a refractory case of COVID-19
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Tocilizumab in a Child with Acute Leukoencephalopathy with Restricted Diffusion
por: Jaiswal, Anshul, et al.
Publicado: (2023)

Several potential risks of novel coronavirus (COVID-19) pneumonia outbreaks in hospitals
por: Wen, Xianjie, et al.
Publicado: (2020)

Dexametasona frente a metilprednisolona ajustada al peso en pacientes con neumonía moderada-grave por SARS-CoV-2
por: Aomar-Millán, Ismael F., et al.
Publicado: (2023)

Prediction of moderately severe and severe acute pancreatitis in pregnancy: Several issues
por: Yang, Qun-Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ds3emj36t7esv1lsj323bh2j4r